Found: 51
Select item for more details and to access through your institution.
Correction: Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: A prospective cohort study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: A prospective cohort study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. 562, doi. 10.1002/ajh.26491
- By:
- Publication type:
- Article
Biclonal lymphoproliferative disorders: another association with NOTCH1-mutated chronic lymphocytic leukaemias.
- Published in:
- Irish Journal of Medical Science, 2021, v. 190, n. 3, p. 1087, doi. 10.1007/s11845-020-02386-1
- By:
- Publication type:
- Article
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.802906
- By:
- Publication type:
- Article
Cutaneous hypereosinophilia secondary to a low‐grade B‐cell lymphoma.
- Published in:
- International Journal of Dermatology, 2019, v. 58, n. 8, p. e146, doi. 10.1111/ijd.14495
- By:
- Publication type:
- Article
Post-operative immune suppression is mediated via reversible, Interleukin-10 dependent pathways in circulating monocytes following major abdominal surgery.
- Published in:
- PLoS ONE, 2018, v. 13, n. 9, p. 1, doi. 10.1371/journal.pone.0203795
- By:
- Publication type:
- Article
The research agenda for trauma critical care.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The human response to infection is associated with distinct patterns of interleukin 23 and interleukin 27 expression.
- Published in:
- Intensive Care Medicine, 2008, v. 34, n. 4, p. 683, doi. 10.1007/s00134-007-0968-5
- By:
- Publication type:
- Article
Neurotrophins and B-cell malignancies.
- Published in:
- Cellular & Molecular Life Sciences, 2016, v. 73, n. 1, p. 41, doi. 10.1007/s00018-015-2046-4
- By:
- Publication type:
- Article
Chronic myelogenous leukaemia--new therapeutic principles.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-33982-y
- By:
- Publication type:
- Article
New developments in the treatment of multiple myeloma - clinical utility of daratumumab.
- Published in:
- Biologics: Targets & Therapy, 2017, v. 11, p. 31, doi. 10.2147/BTT.S97633
- By:
- Publication type:
- Article
Pulmonary hemorrhage in a hemophiliac simulating a lung neoplasm.
- Published in:
- American Journal of Hematology, 2000, v. 64, n. 4, p. 299, doi. 10.1002/1096-8652(200008)64:4<299::AID-AJH10>3.0.CO;2-8
- By:
- Publication type:
- Article
Enhancing Delivery of Small‐Molecule‐ and Cell‐Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies.
- Published in:
- Advanced Therapeutics, 2020, v. 3, n. 11, p. 1, doi. 10.1002/adtp.202000144
- By:
- Publication type:
- Article
Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
- Published in:
- Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2019.01047
- By:
- Publication type:
- Article
P-094: ABT-199 and epigenetic modifiers: promising novel combinations for the treatment of Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S90, doi. 10.1016/S2152-2650(21)02228-X
- By:
- Publication type:
- Article
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
- By:
- Publication type:
- Article
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
- By:
- Publication type:
- Article
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01581-0
- By:
- Publication type:
- Article
Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e159, doi. 10.1016/j.clml.2019.09.266
- By:
- Publication type:
- Article
Mesenchymal Stromal Cell Sialylation Modulates Antitumor Immune Responses In Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e93, doi. 10.1016/j.clml.2019.09.152
- By:
- Publication type:
- Article
Arresting Resistance: Multi-Drug Resistant Organisms in Autologous Stem Cell Transplant Recipients at an Irish Tertiary Referral Centre.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S333, doi. 10.1016/j.clml.2019.07.326
- By:
- Publication type:
- Article
Targeting Selectins and Their Ligands in Cancer.
- Published in:
- Frontiers in Oncology, 2016, p. 1, doi. 10.3389/fonc.2016.00093
- By:
- Publication type:
- Article
An Ounce of Prevention is Worth a Pound of Cure—Universal Health Coverage to Strengthen Health Security.
- Published in:
- Asia & the Pacific Policy Studies, 2018, v. 5, n. 1, p. 155, doi. 10.1002/app5.204
- By:
- Publication type:
- Article
A High Through-Put Screen for Small Molecules Modulating MCM2 Phosphorylation Identifies Ryuvidine as an Inducer of the DNA Damage Response.
- Published in:
- PLoS ONE, 2014, v. 9, n. 6, p. 1, doi. 10.1371/journal.pone.0098891
- By:
- Publication type:
- Article
Perioperative blood transfusion is associated with a gene transcription profile characteristic of immunosuppression: a prospective cohort study.
- Published in:
- Critical Care, 2014, v. 18, n. 5, p. 1, doi. 10.1186/s13054-014-0541-x
- By:
- Publication type:
- Article
Perioperative blood transfusion is associated with a gene transcription profile characteristic of immunosuppression: a prospective cohort study.
- Published in:
- 2014
- By:
- Publication type:
- journal article
The dual inhibitor of the phosphoinositol‐3 and PIM kinases, IBL‐202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 5, p. 654, doi. 10.1111/bjh.15447
- By:
- Publication type:
- Article
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 1, p. 118, doi. 10.1111/bjh.12486
- By:
- Publication type:
- Article
A novel CD2 staining–based flow cytometric assay for assessment of natural killer cell cytotoxicity.
- Published in:
- Journal of Clinical Laboratory Analysis, 2020, v. 34, n. 12, p. 1, doi. 10.1002/jcla.23519
- By:
- Publication type:
- Article
Patient-Initiated Discontinuation of Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia.
- Published in:
- Case Reports in Hematology, 2020, p. 1, doi. 10.1155/2020/9571691
- By:
- Publication type:
- Article
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 3, p. 421, doi. 10.1007/s00262-019-02477-8
- By:
- Publication type:
- Article
Corrigendum to "Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways".
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
- Published in:
- Journal of Immunology Research, 2020, p. 1, doi. 10.1155/2020/4598476
- By:
- Publication type:
- Article
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
- Published in:
- Journal of Immunology Research, 2020, p. 1, doi. 10.1155/2020/4598476
- By:
- Publication type:
- Article
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Adoptive Immunotherapy and High-Risk Myeloma.
- Published in:
- Cancers, 2023, v. 15, n. 9, p. 2633, doi. 10.3390/cancers15092633
- By:
- Publication type:
- Article
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 2154, doi. 10.3390/cancers15072154
- By:
- Publication type:
- Article
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1568, doi. 10.3390/cancers13071568
- By:
- Publication type:
- Article
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models.
- Published in:
- Cancers, 2013, v. 5, n. 3, p. 901, doi. 10.3390/cancers5030901
- By:
- Publication type:
- Article
The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis.
- Published in:
- Cancers, 2011, v. 3, n. 1, p. 1329, doi. 10.3390/cancers3011329
- By:
- Publication type:
- Article
Frontline Science: COVID‐19 infection induces readily detectable morphologic and inflammation‐related phenotypic changes in peripheral blood monocytes.
- Published in:
- Journal of Leukocyte Biology, 2021, v. 109, n. 1, p. 13, doi. 10.1002/JLB.4HI0720-470R
- By:
- Publication type:
- Article
Targeting AML through DR4 with a novel variant of rhTRAIL.
- Published in:
- Journal of Cellular & Molecular Medicine, 2011, v. 15, n. 10, p. 2216, doi. 10.1111/j.1582-4934.2010.01211.x
- By:
- Publication type:
- Article
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
ADAM17-Mediated Reduction in CD14<sup>++</sup>CD16<sup>+</sup> Monocytes ex vivo and Reduction in Intermediate Monocytes With Immune Paresis in Acute Pancreatitis and Acute Alcoholic Hepatitis.
- Published in:
- Frontiers in Immunology, 2019, p. 1, doi. 10.3389/fimmu.2019.01902
- By:
- Publication type:
- Article
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2019, v. 10, p. 1, doi. 10.1177/2040620719854171
- By:
- Publication type:
- Article
PSGL-1 decorated with sialyl Lewis<sup>a/x</sup> promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-52212-2
- By:
- Publication type:
- Article
Drugging the unfolded protein response in acute leukemias.
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 1, doi. 10.1186/s13045-015-0184-7
- By:
- Publication type:
- Article